Risk of prostate cancer associated with benign prostate disease: A primary care case-control study

British Journal of General Practice

Volumn 61, Issue 592, 2011, Pages

  Buckley, Brian S ^a,b   Lapitan, Marie Carmela M ^b   Simpson, Colin R ^c   Sheikh, Aziz ^c  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Primary health care; Prognosis; Prostate specific antigen; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FAMILY PRACTICE; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; SCOTLAND;

EID: 83355167006     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp11X606573     Document Type: Article

References (44)

1. Naslund MJ, Gilsenan AW, Midkiff KD, et al. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract 2007; 61(9): 1437-1445. (Pubitemid 47228620)
2. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173(4): 1256-1261. (Pubitemid 40380548)
3. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001; 58(suppl 6a): 5-16. (Pubitemid 34007591)
4. Bright E, Abrams P. Diseases of the prostate. Rev Clin Gerontol 2010; 20: 10-19.
5. Young JM, Muscatello DJ, Ward JE. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int 2000; 85(9): 1037-1048. (Pubitemid 30348795)
6. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003; 361(9366): 1359-1367. (Pubitemid 36514874)
7. Alcaraz A, Hammerer P, Tubaro A, et al. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009; 55(4): 864-875.
8. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118(10): 793-803. (Pubitemid 23135479)
9. Andriole G, Brawley O, Tammela T, Rittmaster R. Baseline characteristics of patients in the REDUCE chemoprevention study. Eur Urol 2005; 4(suppl 3): 184.
10. Habuchi T, Liqing Z, Suzuki T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000; 60(20): 5710-5713.
11. Prakash K Pirozzi G, Elashoff M, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A 2002; 99(11): 7598-7603.
12. Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004; 64(3): 537-541.
13. Canby-Hagino E, Hernandez J, Brand TC, Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007; 51(1): 27-33. (Pubitemid 44821534)
14. Haas GP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin 1997; 47(5): 273-287. (Pubitemid 27405933)
15. Hammarsten J, Hogstedt B. Calculated fast-growing benign prostatic hyperplasia - a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 2002; 36(5): 330-338. (Pubitemid 35373619)
16. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41(18): 2887-2895. (Pubitemid 41713128)
17. Guess HA. Benign prostatic hyperplasia and prostate cancer. Epidemiol Rev 2001; 23(1): 152-158. (Pubitemid 32906628)
18. Hamilton W, Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract 2004; 54(505): 617-621. (Pubitemid 39117573)
19. Adolfsson J, Garmo H, Varenhorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007; 41(6): 456-477. (Pubitemid 350207540)
20. Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007; 167(22): 2497-2502. (Pubitemid 350254910)
21. Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst 2005; 97(17): 1236-1237.
22. Buckley BS. Conventional medicine is less than perfect. [commentary] Br J Gen Pract 2009; 59(564): 519.
23. Barry MJ. Prostate specific antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344(18): 1373-1377. (Pubitemid 32378393)
24. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2008; 149(3): 185-191.
25. Chokkalingam AP, Nyren O, Johansson J-E, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia. A population-based cohort study in Sweden. Cancer 2003; 98(8): 1727-1734. (Pubitemid 37238630)
26. ISD Scotland. General practice - practice team information (PTI). http://www.isdscotland.org/pti (accessed 5 May 2011).
27. Whitelaw FG, Nevin SL, Milne RM, et al. Completeness and accuracy of morbidity and repeat prescribing records held on general practice computer systems in Scotland. Br J Gen Pract 1996; 46(404): 181-186. (Pubitemid 26092859)
28. Harley K, Jones C. Quality of Scottish Morbidity Record (SMR) data. Health Bull 1996; 54(5): 410-417.
29. McAlister FA, Murphy NF, Simpson CR, et al. The influence of socioeconomic deprivation on the primary care burden and treatment of heart failure in Scotland. BMJ 2004; 328(7448): 1110-1112.
30. The Scottish Government. Scottish Index of Multiple Deprivation 2006: general report. Edinburgh: The Scottish Government, 2006. http://www.scotland. gov.uk/Publications/2006/10/13142739/1 2006 (accessed 5 May 2011).
31. Donnelley R. Scottish Index of Multiple Deprivation 2009: general report. Edinburgh: The Scottish Government, 2009. http://www.scotland.gov.uk/ Publications/2009/10/28104046/14 (accessed 5 May 2011).
32. Garraway WM, Russell EBAW, Lee RJ, et al. Impact of previously unrecognised benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43(373): 318-321. (Pubitemid 23246559)
33. Alcaraz A, Hammerer P, Tubaro A, et al. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009; 55(4): 864-875.
34. Lourenco T, Armstrong N, N'Dow J, et al. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess 2008; 12(35): iii, ix-x, 1-146, 169-515.
35. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003; 361(9366): 1359-1367. (Pubitemid 36514874)
36. Glaziou P. Sampsize home page. http://sampsize.sourceforge.net (accessed 5 May 2011).
37. ISD. Cancer Incidence (2005). Edinburgh: ISD Online Information and Statistics Division, NHS Scotland, 2007. http://www.isdscotlandarchive.scot.nhs. uk/isd/183.html (accessed 21 Sep 2011).
38. Buckley BS, Simpson CR, McLernon DJ, et al. Five year prognosis in patients with angina identified in primary care: incident cohort study. BMJ 2009; 339(7718): 438-441.
39. Burfor DC, Kirby M, Austoker J. Prostate cancer risk management programme information for primary care; PSA testing in asymptomatic men - evidence document. London: NHS Cancer Screening Programmes, 2009. http://www. cancerscreening.nhs.uk/prostate/pcrmp02.pdf (accessed 21 Sept 2011).
40. Cancer incidence in Wales, 2002-2006. Cardiff: Welsh Cancer Intelligence and Surveillance Unit, 2008.
41. Cancer incidence and mortality. Belfast: Northern Ireland Cancer Registry, Queen's University Belfast, 2008.
42. Office for National Statistics. Cancer Statistics registrations: registrations of cancer diagnosed in 2005. London: Office for National Statistics, 2008.
43. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349(4): 366-381. (Pubitemid 36886244)
44. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8(3): 439-443.